Background Thiopurine methyltransferase (TPMT) catalyses the S-methylation of 6-thiopurine drugs, which are commonly used in the treatment of autoimmune diseases, leukaemia and organ transplantation. TPMT activity is polymorphic as a result of gene mutations. Ethnic variations in phenotype and genotype have been identified in previous population studies, but no information was available within Latin-American populations.
Introduction
Thiopurine S-methyltransferase (TPMT, EC 2.1.1.67) is a cytosolic enzyme that catalyses the S-methylation of aromatic and heterocyclic sulphhydryl compounds, including the thiopurine drugs 6-mercaptopurine (6MP) and 6-thioguanine. 1, 2 6MP is a well-known drug in the treatment of acute lymphoblastic leukaemia. 3^5 Azathioprine (a prodrug of 6MP) is widely used as an immunosuppressive agent in rheumatological diseases, during posttreatment of renal transplantation, and in a variety of dermatological conditions. 6^9 Azathioprine is converted rapidly to 6MP in vivo. 6MP can be converted by various pathways (see Fig. 1 ): it can be metabolized to 6-thioguanine nucleotides, a multistep conversion initially catalysed by hypoxanthineguanine phosphoribosyltransferase; it can be converted to 6-mercapto-8-hydroxypurine and thiouric acid by xanthine oxidase; or it can be 6-Smethylated to 6-methylmercaptopurine (6MeMP) by TPMT. 10 TPMT activity shows a co-dominant genetic polymorphism that is an important factor responsible for large individual di¡erences in thiopurine toxicity and therapeutic e¤cacy. 11, 12 TPMT-de¢cient patients accumulate excessive amounts of thioguanine nucleotides in haematopoietic tissues, leading to severe haematopoietic toxicity when these patients are treated with standard doses of thiopurines such as 388 &2003 The Association of Clinical Biochemists Original Article azathioprine and 6MP; however, these de¢cient patients can be successfully treated with a 10-15-fold lower dosage of these medications. 13^15 Several mutant alleles for low TPMT activity have been identi¢ed (see Table 1 ). 16 However, the frequency and pattern of mutant TPMT alleles are di¡erent among various ethnic populations. Approximately one in 300 Caucasians is homozygous for the allele or alleles for the trait of very low activity and 11% of subjects are heterozygous and have an intermediate TPMT activity. 11 TPMT*3A appears to be the predominant mutant allele in the Caucasian population. South-West Asians have a lower frequency of mutant TPMT alleles and all alleles identi¢ed to date are TPMT*3A; in the East and West African population the frequency of mutant alleles is similar to that of Caucasians, but all mutant alleles are TPMT*3C. Among African-Americans, TPMT*3C is the most prevalent, but TPMT*2 and TPMT*3A are also found. TPMT*4 -*8 have been identi¢ed in isolated subjects with intermediate TPMT activity. 16 The purpose of the present study was to establish the genetic polymorphism of TPMT in an Argentine population, by measuring the TPMT activity, identifying mutant alleles and determining their frequency.
Material and methods

Study population
The study included 147 Argentine healthy blood donors (61 men, 89 women; mean age 31¢6 years, range 8 months to 74 years). The racial-ethnic composition of the individuals in this study was European (Spanish and Italian, especially), Amerindian and a small group of Middle East origin. For the assay of TPMT activity, heparinized venous blood samples (5 mL) were collected and the red blood cells (RBC) were removed, washed and lysed according to the previously described method; 17 the lysate was frozen at 7708C until assay. For molecular analysis, 2 mL of EDTA blood were obtained from the volunteers. Genomic DNA was extracted using the Wizard Genomic DNA Promega Puri¢cation Kit (Promega, Madison, WI, USA).
All subjects or their parents gave their consent for this study.
TPMT enzymatic assay
TPMT activity was measured using a high-performance liquid chromatography (HPLC) method according to Keizer-Garritsen et al. 17 The assay is based on methylation of 6MP with S-adenosyl-Lmethionine as the methyl donor. Allopurinol (inhibitor of xanthine oxidase) and dithiothreitol (protection of the SH-group of 6MP) were added to the incubation mixture. Quanti¢cation of the product (6MeMP) was performed using a Hewlett Packard 1100 HPLC system. The enzymatic assays were performed in triplicate. 
Molecular analysis
For mutational analysis allele-speci¢c polymerase chain reaction (ASA-PCR) and PCR-restriction fragment length polymorphism (PCR-RFLP) were used. TPMT*2, *3A, *3B and *3C mutations were screened according to the method described by Yates et al. 18 TPMT*4, *5, *6, *7 and *8 were detected with selective ampli¢cation in order to create a speci¢c restriction site. 19
Statistical analysis
The Kruskal-Wallis test was used to test for di¡erences between sex and age categories.
Results
The TPMT enzymatic phenotype was determined in 147 healthy blood donors (see Fig. 2 ). All subjects had detectable TPMT activity (range 3¢9-18¢6 pmol6 10 77 RBC6h 71 ). This variation was neither age (Pˆ0¢61) nor gender (Pˆ0¢69) regulated. In the Caucasian, African and Asian populations, the frequency distribution in TPMT activity has been described as trimodal; 11 approximately 84 -89% of the normal population appears to be homozygous for the wild-type (TPMT* 3 and 4) . TPMT*3A was the most prevalent mutant allele (nˆ9); the others were either TPMT*2 (nˆ2) or TPMT*4 (nˆ1).
TPMT*3B, *3C, *5, *6, *7 and *8 were not found in this study. None of the mentioned, so-called known mutations, was found in the samples of the other nine subjects with intermediate activity. As Fig. 4 shows, all 28 subjects with normal activity had a wild-type genotype (TPMT*1/*1).
The allele frequencies were: TPMT*3A, 9/294 (3¢06%); TPMT*2, 2/294 (0.68%); TPMT*4, 1/294 (0¢34%).
We also studied six family members of one of the individuals with TPMT*2 mutation and the parents of the subject with TPMT*4 mutation. In the ¢rst case, two members of this family (father and uncle) were heterozygous for allele TPMT*2; they also had intermediate TPMT activity (7¢0 and 4 ¢ 6 pmol610 77 RBC6h 71 , respectively). In the second family, the mother of the subject was heterozygous for allele TPMT*4 (TPMT activity 4¢6 pmol610 77 RBC6h 71 ).
Discussion
Several ongoing studies aim to identify additional mutant alleles and determine their frequency in various ethnic groups and to de¢ne the molecular mechanisms of TPMT regulation. Polymorphism studies in Latin America have not been performed. There is a previous study of TPMT phenotype only of Brazilians, 20 but this population has a di¡erent ethnic origin from the Argentine population. Argentina was originally a Spanish colony, but since the late nineteenth century it has received major immigration waves from Italy, Spain and, less extensively, from Central and Eastern Europe and the Middle East (i.e. Syria and the Lebanon). The ethnic origin of the Argentine population is therefore highly heterogeneous as, besides the immigrants mentioned above, it includes Amerindian groups, resulting in a complex admixture of races. 21 In the present study, we analysed the genetic polymorphism of TPMT in 147 Argentine subjects who came from di¡erent regions of the country, representing the heterogeneous ethnic origin of this population. Overall, 8¢2% of the Argentine subjects were heterozygous for the studied variant TPMT alleles. Comparison of the mutation frequencies obtained in this study with those reported in di¡erent ethnic groups showed considerable di¡erences between the Argentine and other populations (see Table 2 ). However, there were subjects with an intermediate activity but with no known mutations showing genotype -phenotype discrepancies. Such discordances are due to the fact that the mutant TPMT alleles are not the only factors regulating catalytic activity; other components, such as promoter polymorphisms and new mutations, could also play a role. 29 Recent studies have postulated that a variable number of tandem repeats in the promoter region of the human TPMT gene could modulate the level of TPMT activity. 30, 31 This Argentine study contributes more data on inter-ethnic variations in TPMT polymorphis m. Prospective identi¢cation of such variations may in£uence both the clinical e¤cacy and toxicity of thiopurine drugs. 
